[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022003270A - Compuesto de amida heterocíclica, sal farmacéuticamente aceptable delmismo y método de preparación y uso del mismo. - Google Patents

Compuesto de amida heterocíclica, sal farmacéuticamente aceptable delmismo y método de preparación y uso del mismo.

Info

Publication number
MX2022003270A
MX2022003270A MX2022003270A MX2022003270A MX2022003270A MX 2022003270 A MX2022003270 A MX 2022003270A MX 2022003270 A MX2022003270 A MX 2022003270A MX 2022003270 A MX2022003270 A MX 2022003270A MX 2022003270 A MX2022003270 A MX 2022003270A
Authority
MX
Mexico
Prior art keywords
preparation
pharmaceutically acceptable
acceptable salt
method therefor
amide compound
Prior art date
Application number
MX2022003270A
Other languages
English (en)
Inventor
Wenhu Duan
Meiyu Geng
Jian Ding
Yan Zhang
Huibin Zhang
Zuoquan Xie
Jinpei Zhou
Yifei Yang
Xiyuan Wang
Xiaojun Yang
Zhaoxue Hu
Original Assignee
Shanghai Inst Materia Medica Cas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Inst Materia Medica Cas filed Critical Shanghai Inst Materia Medica Cas
Publication of MX2022003270A publication Critical patent/MX2022003270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan un compuesto de amida heterocíclica de fórmula general (I), una sal farmacéuticamente aceptable del mismo y un método de preparación para el mismo, y el uso del compuesto en la preparación de un fármaco para tratar enfermedades relacionadas con la actividad de STING, en la preparación de un adyuvante inmunológico, y en la preparación de un fármaco para activar STING.
MX2022003270A 2019-09-19 2020-09-21 Compuesto de amida heterocíclica, sal farmacéuticamente aceptable delmismo y método de preparación y uso del mismo. MX2022003270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910891002.7A CN112521394A (zh) 2019-09-19 2019-09-19 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
PCT/CN2020/116614 WO2021052501A1 (zh) 2019-09-19 2020-09-21 杂环酰胺类化合物、其可药用的盐及其制备方法和用途

Publications (1)

Publication Number Publication Date
MX2022003270A true MX2022003270A (es) 2022-07-04

Family

ID=74883932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003270A MX2022003270A (es) 2019-09-19 2020-09-21 Compuesto de amida heterocíclica, sal farmacéuticamente aceptable delmismo y método de preparación y uso del mismo.

Country Status (10)

Country Link
US (1) US20220389025A1 (es)
EP (1) EP4032890A1 (es)
JP (1) JP2022549030A (es)
KR (1) KR20220097388A (es)
CN (2) CN112521394A (es)
AU (1) AU2020348825B2 (es)
BR (1) BR112022005182A2 (es)
CA (1) CA3151776C (es)
MX (1) MX2022003270A (es)
WO (1) WO2021052501A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112521394A (zh) * 2019-09-19 2021-03-19 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
US12065427B2 (en) * 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
CN116332885A (zh) * 2023-02-13 2023-06-27 中国海洋大学 一种硝基杂环类sting激动剂及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808621TA (en) * 2016-04-07 2018-10-30 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
WO2019069275A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited STING AGONIST ADMINISTRATION METHODS
CN110016025B (zh) * 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
WO2020028566A1 (en) * 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
CN112521394A (zh) * 2019-09-19 2021-03-19 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途

Also Published As

Publication number Publication date
KR20220097388A (ko) 2022-07-07
CN112521394A (zh) 2021-03-19
US20220389025A1 (en) 2022-12-08
CN114981273A (zh) 2022-08-30
EP4032890A1 (en) 2022-07-27
WO2021052501A1 (zh) 2021-03-25
CN114981273B (zh) 2024-03-01
AU2020348825B2 (en) 2023-12-21
CA3151776A1 (en) 2021-03-25
BR112022005182A2 (pt) 2022-06-14
AU2020348825A1 (en) 2022-04-28
JP2022549030A (ja) 2022-11-22
CA3151776C (en) 2024-04-09

Similar Documents

Publication Publication Date Title
NZ796075A (en) Five-membered heteroaromatic imidazole compound and use thereof
MX2021000148A (es) Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
MX2022003270A (es) Compuesto de amida heterocíclica, sal farmacéuticamente aceptable delmismo y método de preparación y uso del mismo.
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
SA520411843B1 (ar) Trpc6 مشتقات بيريدين كربونيل والاستخدام الطبي لها كمثبطات
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
MX2024009886A (es) Derivados de quinolina como inhibidores de integrina alfa4beta7.
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2015015168A (es) Derivados heterociclicos y sus usos.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
SA519402090B1 (ar) مثبطات انتقائية لـ hdac6، وطريقة تحضيرها، واستخدامها
MX2018013325A (es) Derivados de adenina como inhibidores de proteína quinasa.
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
MY162554A (en) Novel benzamide derivatives
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
MX2024001352A (es) Inhibidor novedoso de la poli(adp-ribosa) polimerasa y uso del mismo.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
EA202091293A1 (ru) Производные пиридинона и их применение в качестве селективных ингибиторов alk-2
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MX2022009898A (es) Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.